 Extra-striatal PDE10A expression is detectable by [ 
C]IMA107, we
investigated the in-vivo extra-striatal expression of PDE10A in 12 early premanifest HD gene carriers.
Image processing and kinetic modelling was performed using MIAKAT TM . Parametric images of areas for the regulation of cognitive and limbic function that is impaired in HD. Our findings suggest that dysregulation of PDE10A mediated intracellular signalling could be an early phenomenon in the course of HD with relevance also for extra-striatal brain areas.
Introduction
The intracellular enzyme phosphodiesterase 10A (PDE10A) is responsible for the hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), and thus plays a role in regulating cyclic-nucleotide mediated intracellular signalling cascades serving a number of gene transcription factors and neurotransmitter receptors (1) . PDE-10A has the potential to play a crucial role in mechanisms modulating motor, cognitive and neuropsychiatric functions associated with Huntington's disease (HD). Recently, in vivo molecular imaging studies with PET have demonstrated 30-70% reduction of striatal PDE10A in HD gene carriers spanning from far onset premanifest (2) to near onset premanifest and early manifest (3) and advanced manifest (4) stages.
Although PDE10A is mainly expressed in striatal medium spiny neurons, previous work in wild-type and HD animal models have reported PDE10A protein expression in extra-striatal brain areas (5-7).
Evidence from human post-mortem data has shown PDE10A immunoreactivity is detectable at low concentrations in extra-striatal regions including cortical neurons (7, 8) . Furthermore, in experimental studies PDE10A inhibition enhances cAMP response element-binding protein (CREB)-mediated signalling in cortical neurons of HD animal models indicating a direct effect of PDE10A on cortical neuronal survival (5, 9). Therefore, loss of extra-striatal PDE10A expression could be an important pathophysiological feature in the course of HD.
In this study we assessed extra-striatal PDE10A expression in a group of normal controls using 
Methods

Participants
Twelve early, far onset premanifest HD gene carriers were identified from the HD gene carrier registry database of National Hospital of Neurology and Neurosurgery, Queen Square, London. The time to symptom onset was estimated using a validated variant of the survival analysis formula, previously described (2). All early premanifest HD gene carriers were clinically asymptomatic ( Table   1 ). Twelve healthy individuals matched for age and gender served as the control group. Full inclusion and exclusion criteria previously reported (2) . Written informed consent was obtained from all study participants in accordance with the Declaration of Helsinki. The study was approved by the institutional review boards and the research ethics committee. 
Clinical assessments
Motor function was assessed with the UHDRS TMS (10). Functional capacity was assessed with clinician-based Total Functional Capacity scale (TFC), Independence Scale (IS), UHDRS functional assessment (10), and participant self-reported 36-Item Short Form Health Survey (SF-36) (11).
Neuropsychiatric symptoms were evaluated with the shortened form of the problem behaviour assessment (PBA) (12) , the Beck Depression Inventory-II (BDI-II) (13) , and the Hamilton Depression
Rating Scale (HDRS) (14) . Cognitive assessments were carried out using the Cambridge processing (Graded Naming Test).
Scanning procedures
PET and MR imaging was performed at Imanova Ltd, London, UK. Details of PET and MRI scanners have been described previously (2) . In brief, following an intravenous bolus mean dose of ±258 MBq 
Imaging data analysis
Image processing and kinetic modelling was carried out using the Molecular Imaging and Kinetic (18), and the individual subject. All images were checked following spatial normalization to ensure registration accuracy. Individual PET frames were corrected for head motion using frame-by-frame rigid registration using a frame with high signal-to-noise ratio as reference. PET images were anatomically co-registered and to the corresponding MPRAGE MRI and subsequently spatially normalised into the T1-weighted MNI space. confirming the suitability of the cerebellum as a reference region for the determination of the regional estimation of BP ND .
Region of interest analysis
The anatomical CIC atlas version 1. 
MRI volumetric analysis
Since PDE10A is an intracellular enzyme, neuronal loss may affect its expression. We investigated volumetric changes in extra-striatal regions in our cohort of premanifest HD gene carriers compared to healthy controls. Volumetric ROIs were bilaterally defined on each subjects volumetric T1-weighted MRI using the CIC v1.2 atlas. Volumes were extracted and corrected for total intracranial volume using validated methods (22). Benjamini-Hochberg correction to reduce the false discovery rate (24) . The false discovery rate cutoff was set at 0.05. For all comparisons the level α was set at P<0.05; all data presented as mean±SD.
Statistical analysis
Results
8
Clinical measures
No significant differences were found between early premanifest HD gene carriers and healthy controls in motor and functional (P>0.10), neuropsychiatric (P>0.10) and cognitive (P>0.10) assessments (previously reported (2)).
MRI volumetric analysis
Grey and white matter volumetric brain changes have been reported as one of the earliest changes in HD (25) with volumetric changes occurring in cortical regions (26, 27) . Therefore it was important to identify if the cohort of premanifest HD gene carriers had significant volumetric changes, which could be a potential confounding factor when measuring intracellular PDE10A expression. MRI volumetric analysis confirmed there was no significant volume change in any extra-striatal regions between the groups of early premanifest HD gene carriers and healthy controls (P >0.10) (Supplementary Table   S1 ).
Extra-striatal PDE10A expression
Extra-striatal brain regions meeting the threshold criteria in healthy controls, [ 
Discussion
Using non-invasive imaging, we demonstrated significant loss of extra-striatal PDE10A expression, specifically 25% loss in the insular cortex and 42% loss in the occipital fusiform gyrus, in early premanifest HD gene carriers who were several years before their predicted symptomatic onset. We did not detect significant volume change in our HD gene carriers, indicating that showed loss of metabolic activity in the insula while the occipital cortex showed increased metabolic activity in early premanifest HD gene carriers (34) . fMRI studies report reduced neural activity in the insula of early premanifest HD (35) , and reduced neuronal activity within the fusiform cortex (28) and occipital cortex (36) in early manifest HD. Results from the present study suggest dysregulation of PDE10A also occurs in the insula and occipital fusiform gyrus; however the relationship between these pathophysiological events is currently unknown.
PDE10A has a key role in regulating intracellular signalling and given the functional significance of the insula and occipital fusiform gyrus, loss of PDE10A expression reported here could be an early phenomenon underlying subsequent development of cognitive and behavioural symptoms in the course of HD. In our study we did not find associations between loss of PDE10A expression in the insula or occipital fusiform gyrus and cognitive and behavioural performance as measured by specialised tools. However, our sample size was relatively small and premanifest HD gene carriers at a far onset stage with intact brain functions. Our design is limited due to the cross-sectional nature; however, it could be possible that future prospective studies may show that loss of PDE10A expression in the insula and occipital fusiform gyrus are associated with the risk of developing cognitive and behavioural issues in manifest HD. Furthermore, in HD the affected extra-striatal regions could play a role in visuomotor (37), visuospatial (38) and oculomotor (39, 40) , as well as facial expression deficits (41, 42) . In the present study we did not examine visual function or face recognition. Therefore, further studies with specific clinical measures assessing such deficits may highlight clinical associations. 13 To support the reliability of our data, we demonstrated that loss of [ A recent one year follow-up study demonstrated a mean annual loss of PDE10A of 16.6% in the caudate, 6.9% in the putamen and 5.8% in the globus pallidus (43) . Furthermore, two genetic studies have identified PDE10A mutations as a cause of hyperkinetic movement disorders (44, 45) confirming the role of PDE10A in regulating striato-cortical activity and supporting an important role of PDE10A in the pathophysiology of HD. Findings that PDE10A changes can be detected outside the striatum, even at early premanifest stages, further increases the value of PDE01A as a biomarker to track disease progression in HD.
In conclusion, we provide in vivo evidence for the loss of PDE10A expression in insula and occipital fusiform gyrus a number of years before symptomatic onset in premanifest HD gene carriers. Further studies are needed to explore the relevance of extra-striatal PDE10A loss in the development of cognitive and behavioural symptoms. This study supports the increasing evidence for the role of PDEs in neurodegenerative disorders and the use of [ 11 C]IMA107 PET as a robust imaging tool to study PDE10A in vivo in the human brain and disease.
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